Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

Background: Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin's lymphoma (HL) remain controversial. Patients and Methods: We sought individual patient data from randomised tri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2006-12, Vol.17 (12), p.1749-1760
Hauptverfasser:	Franklin, J, Pluetschow, A, Paus, M, Specht, L, Anselmo, A-P, Aviles, A, Biti, G, Bogatyreva, T, Bonadonna, G, Brillant, C, Cavalieri, E, Diehl, V, Eghbali, H, Fermé, C, Henry-Amar, M, Hoppe, R, Howard, S, Meyer, R, Niedzwiecki, D, Pavlovsky, S, Radford, J, Raemaekers, J, Ryder, D, Schiller, P, Shakhtarina, S, Valagussa, P, Wilimas, J, Yahalom, J
Format:	Artikel
Sprache:	eng
Schlagworte:	chemotherapy Combined Modality Therapy Hodgkin Disease - drug therapy Hodgkin Disease - radiotherapy Hodgkin Disease - therapy Hodgkin's lymphoma Humans meta-analysis Neoplasms, Second Primary - epidemiology radiotherapy Randomized Controlled Trials as Topic second malignancies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!